What Alpharma Llc does

AlPharma LLC (ООО «АЛФАРМА») is a privately held Russian pharmaceutical company founded in 2004 and headquartered in Moscow, focused on developing, manufacturing, and supplying antibacterial, oncological, and other pharmaceutical drugs to the hospital sector. The company operates a full-cycle vertically integrated model spanning fundamental science, applied research, and GMP-certified manufacturing conducted through its subsidiary AO Altegra in the Dubna Special Economic Zone (Moscow Oblast), which produces over 900,000 vials of antibiotics per month and has produced more than 30 preparations over five years. The portfolio includes approximately 30 drug preparations, notably original antibiotic combinations such as Klaruktam (cefotaxime+sulbactam) and Maksiktam-AF (cefepime+sulbactam), which are incorporated into Russian clinical guidelines and treatment standards, alongside a generic portfolio covering carbapenems, glycopeptides, antifungals, and antiretrovirals. Three of the company's products are on the Russian List of Essential Medicines (ZHNVLP).

The business model is enterprise B2B-focused: products are sold via direct field sales to over 900 healthcare institutions (LPUs) across 89 regions of Russia, supplemented by distribution partnerships with major Russian pharmaceutical wholesalers including Protek and R-Pharm. Products are registered in five international markets (Azerbaijan, Armenia, Kyrgyzstan, Uzbekistan, Mongolia), with ongoing registration work in additional countries. Pricing is determined through government procurement and tender processes, with no publicly disclosed pricing. Distribution is augmented by partnerships with regional distributors (Pharmforward, Lancet Pharm, Ruzpharma, Evroservice, Dekopharm, Pharmservis, AlGen, Sev-Zap, Long Sheng) and a strategic MoU with Vietnam's Ministry of Industry and Trade. The company reports approximately 400 highly qualified employees, is led by General Director Sidorov Stanislav Mikhailovich, and is privately held with no parent company or institutional investor ownership structure disclosed. Strategic momentum in 2025-2026 includes the launch of a new Altegra production workshop, a 1.8 billion RUB oncology investment via subsidiary Alsigma, a Gazprombank cooperation agreement, and a 945 million RUB FRP grant for a new pharmaceutical complex.

Name

Alpharma Llc

Legal name

OOO «АЛФАРМА»

Website

https://al-farma.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

AlPharma is a Russian pharmaceutical company founded in 2004 that develops, manufactures, and supplies original and generic antibacterial and oncological drugs to over 900 healthcare institutions across Russia and CIS countries via its GMP-certified Dubna facility.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Antibacterial pharmaceuticals
• Oncological pharmaceuticals
• Hospital antibiotics
• Generic drug manufacturing
• GMP pharmaceutical production

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Sale of proprietary and generic antibacterial, oncological, and other pharmaceutical drugs to healthcare institutions (LPU) across Russia and CIS countries. Three drugs are included in the Russian List of Essential Medicines (ZHNVLP).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

AlPharma develops, manufactures, and supplies a portfolio of approximately 30 proprietary and generic antibacterial, oncological, antifungal, antiretroviral, and cardiovascular pharmaceutical preparations. Production is conducted at the GMP-certified AO Altegra facility in the Dubna special economic zone, with a second Alsigma facility under construction for tablet and oncological drugs. The company's flagship offerings are original combination antibiotics (Klaruktam, Maksiktam-AF, Racobaktam) included in Russian clinical treatment standards.

Product overview

AlPharma is a Russian technological pharmaceutical company operating as a comprehensive product portfolio of approximately 30 pharmaceutical preparations. The company develops, manufactures, and markets both original branded preparations and generic drugs. Original preparations include key hospital antibiotics such as Кларуктам (cefotaxime+sulbactam), Максиктам-АФ (cefepime+sulbactam), Рацобактам (piperacillin+tazobactam), Пазутренд (pazufoxacin), Азликтера and АЛСПЕКРОРЕН (aztreonam), and others. The generic portfolio includes antibiotics (meropenem, doripenem, vancomycin, amoxicillin+sulbactam, ertapenem, tigecycline), antifungals (micafungin, caspominer), antiretroviral drugs (virinoks-AF, raltetress), and other specialty medications. Production is conducted at AO Altegra facility in the Dubna special economic zone with GMP certification. The company also develops two original antibiotics and is expanding into oncological preparations through subsidiary Alsigma.

Differentiator

Problem solved

Functional benefit

Brands

• Klaruktam (Кларуктам): Original combination of cefotaxime and sulbactam for therapy of community-acquired infections in hospital settings
• Maksiktam-AF (Максиктам-АФ)
• Altegra
• Azliktera (Азликтера)

Products and services

• Azliktera (Азликтера) Original aztreonam-based antibiotic indicated for therapy of complex bacterial infections in cystic fibrosis patients.
• Alspekroren 2000 (АЛСПЕКРОРЕН 2000) Original aztreonam antibiotic in a unique 2000mg dosage for practical hospital application.
• Klaruktam (Кларуктам) Original combination of cefotaxime and sulbactam for therapy of community-acquired infections in hospital settings.
• Kolistin-AF / Kolitriven-AF (Колистин-АФ / Колитривен-АФ) Original colistimethate sodium products with adaptive hospital dosages for parenteral therapy of nosocomial infections caused by polyresistant (multidrug-resistant) strains.
• Lanson-AF (Лансон-АФ) Original lansoprazole-based preparation indicated for therapy of gastrointestinal bleedings and acute stress ulcers.
• Maksiktam-AF (Максиктам-АФ) Unique original combination of cefepime and sulbactam for initial empirical therapy of nosocomial pneumonia; became the #1 brand on the Russian hospital antibiotic market within two years of launch.
• MIZIDA-AG (МИЗИДА-АГ) Original cephalosporin-based preparation indicated for treatment of community-acquired infections in comorbid patients.
• Pazutrend (Пазутренд) Original pazufoxacin-based fluoroquinolone positioned as a justified choice with minimal risk and high efficacy.
• Racobaktam (Рацобактам) Original piperacillin + tazobactam combination for initial empirical therapy of severe community-acquired and early nosocomial infections of abdominal and urinary systems, including febrile neutropenia.
• Azakter-AF (Азактер-АФ) Generic aztreonam antibiotic for treatment of infections caused by aztreonam-sensitive aerobic gram-negative microorganisms.
• Altegraklav (Альтеграклав) Generic amoxicillin with clavulanic acid combination for treatment of bacterial infections caused by sensitive microorganisms.
• Alfosimendan (Альфосимендан) Generic levosimendan for short-term treatment of acute decompensation of severe chronic heart failure in adults from 18 years.
• Amoktam (Амоктам) Generic amoxicillin + sulbactam combination as powder for solution for intravenous and intramuscular injection.
• Vankoter-AF (Ванкотер-АФ) Generic vancomycin indicated for treatment of MRSA-associated infections.
• Virinoks-AF (Виринокс-АФ) Generic antiretroviral drug for treatment of HIV infection in adults and children from 3 years as part of combination therapy.
• Doripenem 250 (Дорипенем 250) Generic synthetic carbapenem antibiotic for intravenous administration.
• Kaspominer (Каспоминера) Generic antifungal agent for systemic application.
• Kolistimet AF (Колистимет АФ) Generic colistimethate sodium as powder for solution for injections, infusions, and inhalations.
• Meropenem (Меропенем) Generic synthetic carbapenem antibiotic for intravenous administration in dosages of 250mg, 500mg, and 1000mg.
• Mikafucid 50 (Микафуцид 50) Generic micafungin as lyophilisate for solution for infusions.
• Polimibaksa AF (Полимибакса АФ) Generic polypeptide-structure antibacterial agent for systemic action.
• Raltetress (Ралтетресс) Generic antiretroviral drug for treatment of HIV-1 infection in combination with other antiretroviral drugs.
• Rucektam (Руцектам) Generic ceftriaxone + sulbactam combination as powder for solution for IV and IM administration.
• Sulmagraf (Сульмаграф) Generic cefoperazone + sulbactam combination as powder for solution for IV and IM administration.
• Sulmacefta (Сульмацефта) Generic ampicillin + sulbactam combination as powder for solution for IV and IM administration.
• Tigelin AF 50 (Тигелин АФ 50) Generic tigecycline as lyophilisate for concentrate for solution for infusions.
• Tobraminеr 75 (Тобраминер 75) Generic tobramycin solution for inhalation.
• Fosfocefta (Фосфоцефта) Generic fosfomycin for treatment of infectious-inflammatory diseases caused by fosfomycin-sensitive pathogens.
• Ertam-AF (Эртам-АФ) Generic ertapenem as lyophilisate for solution for IM injection and infusions.

Quantifiable outcome

• More than 770,000 lives saved through use of AlPharma products
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• ProtekcoreChannel Partner/ Reseller/ DistributorProtek is a major Russian pharmaceutical distributor. Listed as a partner in the company's partner network.
• R-PharmcoreChannel Partner/ Reseller/ DistributorR-Pharm is a large Russian pharmaceutical company and distributor. Listed as a partner in the company's partner network.
• PharmforwardminorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Evroservice (Евросервис)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Lancet Pharm (Ланцет Фарм)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Long ShengminorChannel Partner/ Reseller/ DistributorListed as a partner, international distribution partner.
• Ruzpharma (Рузфарма)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Sev-Zap (Севзап)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Dekopharm (Декофарм)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Pharmservis (Фармсервис)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• AlGen (АлДжен)minorChannel Partner/ Reseller/ DistributorListed as a partner in the company's partner network.
• Vietnam Ministry of Industry and TrademinorStrategic or Co-development PartnerMoU signed at Vietnam-Russia Scientific Forum on cooperation in scientific research, industrial development and innovation in the industrial sector. AlPharma participated alongside Rosatom and Rusal.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• R-Pharm: One of Russia's largest pharmaceutical manufacturers and distributors with a broad portfolio including hospital antibiotics and oncology products. Direct competitor in Russian hospital tender markets and listed as a distribution partner for AlPharma.
• Pharmasyntez: Major Russian manufacturer of antibacterial, oncological, and anti-tuberculosis drugs with significant institutional hospital sales. Direct competitor in the same Russian state-tender channel and therapeutic categories as AlPharma.
• Biocad: Leading Russian biotech company producing biologics, oncologicals, and anti-infectives. Competes with AlPharma in oncology and in Russian hospital procurement for advanced therapeutics.
• Valenta Pharm: Russian pharmaceutical manufacturer with branded and generic portfolios across multiple therapeutic areas including anti-infectives. Direct competitor in domestic Russian institutional sales.
• Veropharm: Russian pharmaceutical manufacturer with a generics-heavy portfolio including antibiotics, oncology support, and hospital products. Competes directly with AlPharma in Russian state hospital procurement.

Broad incumbents

• Generium: Larger Russian biopharmaceutical company with a broad portfolio of biologics, gene therapies, and hospital specialty products. Overlaps with AlPharma in advanced hospital therapeutics and Russian institutional channels.
• Protek: Russia's largest pharmaceutical distributor with significant manufacturer and pharmacy operations. Both a distribution partner for AlPharma and a competing broader pharmaceutical group via proprietary and partner products.
• Stada Arzneimittel: European generics and specialty pharmaceutical company with established Russian market presence. Competes across generic antibiotics and hospital specialty products in Russian procurement.

Regional players

• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with significant presence in Russian and CIS markets. Directly competes in hospital generics and antibiotics in the same Russian tender channel.
• Polpharma: Polish generic pharmaceutical manufacturer with broad hospital portfolio and Russian market presence. Competes with AlPharma generics and antibiotics in Russian and CIS institutional channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alpharmarussia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpharma Llc